<DOC>
	<DOCNO>NCT00853125</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Infusing irradiated donor lymphocytes patient may help patient 's immune system kill tumor cell . Giving sunitinib together irradiate donor lymphocyte may kill tumor cell . PURPOSE : This phase II trial study well give sunitinib together irradiate donor lymphocyte work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Sunitinib Irradiated Donor Lymphocytes Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival patient metastatic clear cell renal cell carcinoma treat sunitinib irradiate allogeneic lymphocyte . Secondary - Determine rate kinetics clinical/radiographic response patient . - Determine toxicity associate treatment patient . - Assess stable disease 6 month patient . - Assess overall survival patient . OUTLINE : Patients receive oral sunitinib malate daily 4 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Beginning course 2 sunitinib malate , patient also receive irradiated allogeneic lymphocytes IV 1 hour every 8-16 week 6 infusion absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 60 day .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Primary lesion metastatic site demonstrate clear cell variant &lt; 25 % histology Radiographically measurable disease RECIST criterion Initiated treatment sunitinib malate ≤ 6 week ago No radiographically detectable brain metastasis MRI CT scan HLApartially match related donor available , determine serologic and/or DNA type Appropriate HLA match ( ≥ 2/6 HLA A , B , DR match ) PATIENT CHARACTERISTICS : ECOG performance status 01 Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Total bilirubin ≤ 2.0 time upper limit normal ( ULN ) AST ≤ 3.0 time ULN Calculated creatinine clearance ≥ 40 mL/min Cardiac ejection fraction ≥ 50 % QTc interval &lt; 500 msec EKG Not pregnant Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity None follow within past 6 month : Myocardial infarction Severe/unstable angina Coronary/peripheral artery bypass graft Symptomatic congestive heart failure Cerebrovascular accident transient ischemic attack Pulmonary embolism No ongoing ventricular cardiac dysrhythmias ≥ grade 2 , accord NCI CTCAE v3.0 No history serious ventricular arrhythmia ( e.g. , ventricular tachycardia &gt; 3 beat row ) No ongoing atrial fibrillation No malignancy within past 3 year , basal cell skin cancer , squamous cell skin cancer , situ cervical cancer , ductal lobular carcinoma situ breast No concurrent serious illness PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior systemic therapy metastatic renal cell carcinoma No prior immunotherapy No prior VEGFtargeted mTORtargeted therapy No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) , St. John 's wort , ketoconazole , dexamethasone , dysrhythmic drug ( e.g. , terfenadine , quinidine , procainamide , sotalol , probucol , bepridil , indapamide , flecainide ) , haloperidol , risperidone , rifampin , grapefruit , grapefruit juice No concurrent investigational anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>